AI Engines For more Details: Perplexity Kagi Labs You
Urinary Tract Infections (UTIs): Methenamine is effective in preventing recurrent UTIs, particularly those caused by Escherichia coli. It works by converting to formaldehyde in an acidic environment, which then exerts bactericidal activity against susceptible bacteria in the urinary tract.
Prophylaxis in Patients Prone to UTIs: Methenamine is commonly prescribed as a prophylactic agent for patients who have frequent or recurrent UTIs, especially those with underlying conditions such as neurogenic bladder, urinary retention, or anatomical abnormalities predisposing them to UTIs.
Interstitial Cystitis: Some healthcare providers may prescribe methenamine as part of the treatment regimen for interstitial cystitis, a chronic inflammatory condition of the bladder characterized by pelvic pain, urinary urgency, and frequency.
Cystitis: Methenamine may be used as adjunctive therapy in the treatment of cystitis, an inflammation of the bladder typically caused by bacterial infection.
Prostatitis: In some cases, methenamine may be included in the treatment regimen for chronic prostatitis or chronic pelvic pain syndrome, especially when recurrent UTIs are a complicating factor.
Antibiotic Resistance Prevention: Methenamine has the advantage of not contributing to antibiotic resistance, which is a growing concern with the overuse of traditional antibiotics. It achieves bactericidal effects through a non-antibiotic mechanism.
Safety and Tolerability: Methenamine is generally well-tolerated, with few systemic side effects. However, some individuals may experience gastrointestinal upset, including nausea, vomiting, or abdominal discomfort. Patients should stay adequately hydrated while taking methenamine to minimize the risk of urinary tract irritation.
Monitoring: Regular monitoring of renal function and urinary pH may be necessary during methenamine therapy, especially in patients with renal impairment or metabolic conditions affecting urinary acidity.
Contraindications and Precautions: Methenamine is contraindicated in patients with severe renal impairment, hepatic dysfunction, or urinary obstruction. It should be used cautiously in individuals with a history of urinary stones or metabolic acidosis.
Drug Interactions: Methenamine may interact with certain medications, such as sulfonamides, that alkalinize urine, potentially reducing its effectiveness. It is essential to inform healthcare providers about all medications being taken to avoid potential interactions.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| ADHD | 1.6 | 0.3 | 4.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 2.3 | 0.8 | 1.87 |
| Allergies | 1.7 | 0.9 | 0.89 |
| Allergy to milk products | 1.1 | 1.3 | -0.18 |
| Alzheimer's disease | 1.7 | 3.9 | -1.29 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1 | 0.5 | 1 |
| Ankylosing spondylitis | 2.2 | 1 | 1.2 |
| Anorexia Nervosa | 0.7 | 1.6 | -1.29 |
| Antiphospholipid syndrome (APS) | 1.4 | 0.3 | 3.67 |
| Asthma | 1.7 | 1.1 | 0.55 |
| Atherosclerosis | 1.9 | 1.2 | 0.58 |
| Atrial fibrillation | 1.7 | 2.4 | -0.41 |
| Autism | 4.4 | 4.7 | -0.07 |
| Autoimmune Disease | 0.9 | 0.5 | 0.8 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2 | 2 | |
| Bipolar Disorder | 1.6 | 0.8 | 1 |
| Brain Trauma | 0.8 | 0.8 | 0 |
| Breast Cancer | 0.5 | 0.5 | |
| Carcinoma | 1.9 | 0.7 | 1.71 |
| Celiac Disease | 1.8 | 1 | 0.8 |
| Cerebral Palsy | 0.6 | 0.8 | -0.33 |
| Chronic Fatigue Syndrome | 1.7 | 2.4 | -0.41 |
| Chronic Kidney Disease | 2.6 | 2 | 0.3 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.1 | 1.1 | 0 |
| Chronic Urticaria (Hives) | 1.4 | 0.7 | 1 |
| Coagulation / Micro clot triggering bacteria | 1.8 | 0.8 | 1.25 |
| Cognitive Function | 1 | 0.8 | 0.25 |
| Colorectal Cancer | 3.1 | 1.6 | 0.94 |
| Constipation | 0.9 | 0.5 | 0.8 |
| Coronary artery disease | 2.3 | 1.5 | 0.53 |
| COVID-19 | 2.7 | 3.8 | -0.41 |
| Crohn's Disease | 4.5 | 1.9 | 1.37 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.1 | 0.8 | 0.38 |
| d-lactic acidosis (one form of brain fog) | 0.5 | 0.5 | |
| deep vein thrombosis | 2 | 1.1 | 0.82 |
| Denture Wearers Oral Shifts | 0.3 | 0.3 | |
| Depression | 3.4 | 4.8 | -0.41 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.6 | 0.4 | 3 |
| Endometriosis | 2.4 | 1.3 | 0.85 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 1.8 | 1.3 | 0.38 |
| erectile dysfunction | 0.9 | 0.9 | |
| Fibromyalgia | 1.6 | 1.5 | 0.07 |
| Functional constipation / chronic idiopathic constipation | 3.1 | 2.9 | 0.07 |
| gallstone disease (gsd) | 2.9 | 0.5 | 4.8 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0.3 | -2 |
| Generalized anxiety disorder | 2.6 | 0.9 | 1.89 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1 | 0.3 | 2.33 |
| Graves' disease | 0.7 | 1.1 | -0.57 |
| Gulf War Syndrome | 0.6 | 0.1 | 5 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 1.6 | 1.2 | 0.33 |
| Heart Failure | 3 | 0.8 | 2.75 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 1.4 | 1.4 | |
| High Histamine/low DAO | 2.3 | 2.3 | |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
| hyperglycemia | 1.1 | 0.7 | 0.57 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 2.8 | 1.8 | 0.56 |
| Hypothyroidism | 0.5 | 0.3 | 0.67 |
| Hypoxia | 1.8 | 1.8 | |
| IgA nephropathy (IgAN) | 1 | 1.8 | -0.8 |
| Inflammatory Bowel Disease | 3.4 | 3.8 | -0.12 |
| Insomnia | 0.9 | 1.4 | -0.56 |
| Intelligence | 1.1 | 0.6 | 0.83 |
| Intracranial aneurysms | 0.7 | 0.3 | 1.33 |
| Irritable Bowel Syndrome | 4.1 | 1.8 | 1.28 |
| ischemic stroke | 1.5 | 1.7 | -0.13 |
| Liver Cirrhosis | 3.6 | 2.2 | 0.64 |
| Long COVID | 3.7 | 2.1 | 0.76 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.9 | 0.9 | |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.3 | 2 |
| ME/CFS with IBS | 0.3 | 0.9 | -2 |
| ME/CFS without IBS | 1 | 0.3 | 2.33 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 4.1 | 2.3 | 0.78 |
| Mood Disorders | 2.9 | 4.2 | -0.45 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 1.7 | 2.8 | -0.65 |
| Multiple system atrophy (MSA) | 0.1 | 0.1 | |
| myasthenia gravis | 0.9 | 0.5 | 0.8 |
| neuropathic pain | 1.3 | -1.3 | |
| Neuropathy (all types) | 0.3 | 1.6 | -4.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.8 | 1.9 | 0.47 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 5.6 | 2.7 | 1.07 |
| obsessive-compulsive disorder | 2.2 | 3 | -0.36 |
| Osteoarthritis | 1.8 | 0.6 | 2 |
| Osteoporosis | 1.4 | 0.6 | 1.33 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 5 | 3.9 | 0.28 |
| Polycystic ovary syndrome | 3.8 | 1.4 | 1.71 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 0.3 | 0 |
| Primary sclerosing cholangitis | 1.6 | 1.4 | 0.14 |
| Psoriasis | 0.9 | 2.4 | -1.67 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5 | 1.5 | 2.33 |
| Rosacea | 0.6 | 0.5 | 0.2 |
| Schizophrenia | 1.6 | 1.6 | 0 |
| scoliosis | 1.3 | 0.3 | 3.33 |
| sensorineural hearing loss | 0.5 | 0.5 | |
| Sjögren syndrome | 1.9 | 1 | 0.9 |
| Sleep Apnea | 0.3 | 1.1 | -2.67 |
| Slow gastric motility / Gastroparesis | 0.8 | 0.8 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.9 | 1.9 | |
| Stress / posttraumatic stress disorder | 1.8 | 1.6 | 0.13 |
| Systemic Lupus Erythematosus | 3 | 0.5 | 5 |
| Tic Disorder | 0.3 | 0.6 | -1 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 1.9 | 1.1 | 0.73 |
| Type 2 Diabetes | 4.3 | 2.5 | 0.72 |
| Ulcerative colitis | 2.8 | 2.6 | 0.08 |
| Unhealthy Ageing | 2.6 | 1.5 | 0.73 |
| Vitiligo | 1.1 | 1.1 | 0 |
